Wexford Capital’s Arcus Biosciences RCUS Stock Holding History

Wexford Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,800	Closed	-$397	–	209
2021 Q4	$397	Buy	+9,800	New	+$380K	0.02%	144
2021 Q2	$330K	Buy	+12,000	New	+$343K	0.05%	136
2021 Q1	–	Sell	-5,650	Closed	-$147K	–	316
2020 Q4	$147K	Hold	5,650	–	–	0.02%	154
2020 Q3	$97K	Buy	5,650 +4,400	+352%	+$98.3K	0.03%	158
2020 Q2	$31K	Buy	+1,250	New	+$33.7K	0.01%	166

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Wexford Capital's RCUS Position: Q1 2022 in Review

Wexford Capital sold out of Arcus Biosciences (RCUS) in Q1 2022, closing a stake of 9,800 shares — an estimated $397 sold.

Wexford Capital first reported a position in RCUS in Q2 2020 and held it in 5 quarters. The position peaked at $330K in Q2 2021. 157 funds tracked by Wall St. Rank hold RCUS as of Q1 2022.

Wexford Capital reported no remaining Arcus Biosciences position as of Q1 2022 after selling out during the quarter.
Wexford Capital sold 9,800 Arcus Biosciences shares in Q1 2022, an estimated $397.
Wexford Capital first reported a position in Arcus Biosciences in Q2 2020 and held it in 5 quarters.
Wexford Capital's Arcus Biosciences position peaked at $330K in Q2 2021.
157 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2022.

Based on Wexford Capital's 13F filing for Q1 2022, filed 13 May 2022.